These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 15944867

  • 1. Sibutramine and the sympathetic nervous system in obese humans.
    Haynes WG, Egri Z.
    Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
    [No Abstract] [Full Text] [Related]

  • 2. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
    Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J.
    Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
    [Abstract] [Full Text] [Related]

  • 3. Sibutramine and the management of obesity.
    Poston WS, Foreyt JP.
    Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
    [Abstract] [Full Text] [Related]

  • 4. Sibutramine and blood pressure: a therapeutic dilemma.
    Bray GA.
    J Hum Hypertens; 2002 Jan; 16(1):1-3. PubMed ID: 11840223
    [No Abstract] [Full Text] [Related]

  • 5. Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension.
    Gürsoy A, Erdoğan MF, Cin MO, Cesur M, Başkal N.
    Endocr Pract; 2005 Jan; 11(5):308-12. PubMed ID: 16191490
    [Abstract] [Full Text] [Related]

  • 6. Sibutramine in overweight/obese hypertensive patients.
    Sharma AM.
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S20-3. PubMed ID: 11916102
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 8. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W, Goa KL.
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [Abstract] [Full Text] [Related]

  • 9. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.
    Faria AN, Ribeiro Filho FF, Lerario DD, Kohlmann N, Ferreira SR, Zanella MT.
    Arq Bras Cardiol; 2002 Feb; 78(2):172-80. PubMed ID: 11887193
    [Abstract] [Full Text] [Related]

  • 10. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
    Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, Hanotin C, Igau B, Drouin P.
    Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
    [Abstract] [Full Text] [Related]

  • 11. How does sibutramine work?
    Lean ME.
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S8-11. PubMed ID: 11916106
    [Abstract] [Full Text] [Related]

  • 12. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
    Luque CA, Rey JA.
    Ann Pharmacother; 1999 Sep; 33(9):968-78. PubMed ID: 10492502
    [Abstract] [Full Text] [Related]

  • 13. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A, Lundsgaard C.
    Exp Clin Endocrinol Diabetes; 1998 Sep; 106 Suppl 2():29-34. PubMed ID: 9792479
    [Abstract] [Full Text] [Related]

  • 14. 5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
    Thomas GH, Babbs AJ, Chatfield RE, Krülle TM, Widdowson PS, Provost D, McCormack JG.
    Obesity (Silver Spring); 2009 Mar; 17(3):467-73. PubMed ID: 19219064
    [Abstract] [Full Text] [Related]

  • 15. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 16. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients.
    Guven A, Koksal N, Cetinkaya A, Sokmen G, Ozdemir R.
    Diabetes Obes Metab; 2004 Jan; 6(1):50-5. PubMed ID: 14686963
    [Abstract] [Full Text] [Related]

  • 17. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M, Liberopoulos EN, Elisaf MS.
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [Abstract] [Full Text] [Related]

  • 18. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G, Romano C, De Caprio C, Contaldo F, Salanitri T, di Luzio Paparatti U, Pasanisi F.
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [Abstract] [Full Text] [Related]

  • 19. [Pharma-clinics. Medication of the month. Sibutramine (Reductil)].
    Scheen AJ.
    Rev Med Liege; 2001 Sep; 56(9):656-9. PubMed ID: 11702509
    [Abstract] [Full Text] [Related]

  • 20. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
    Yee BJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR.
    Int J Obes (Lond); 2007 Jan; 31(1):161-8. PubMed ID: 16652122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.